Lynnd Kramer News Today : Breaking News, Live Updates & Top

BioArctic: Full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease published in the New England Journal of Medicine

Published: November 30, 2022

STOCKHOLM, Nov. 30, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory

Source: finanznachrichten.de

Lynnd Kramer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top News In Lynnd Kramer Today - Breaking & Trending Today

Full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease published in the New England Journal of Medicine

BioArctic: Full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease published in the New England Journal of Medicine